C3G Is Upregulated in Hepatocarcinoma, Contributing to Tumor Growth and Progression and to HGF/MET Pathway Activation

Impacto

Downloads

Downloads per month over past year

Sequera, Celia and Bragado Domingo, Paloma and Manzano, Sara and Arechederra, Maria and Richelme, Sylvie and Gutierrez Uzquiza, Álvaro and Sánchez Muñoz, Aránzazu and Maina, Flavio and Guerrero, Carmen and Porras Gallo, Almudena (2020) C3G Is Upregulated in Hepatocarcinoma, Contributing to Tumor Growth and Progression and to HGF/MET Pathway Activation. Cancers, 12 (8). p. 2282. ISSN 2072-6694

[thumbnail of cancers-12-02282-v2.pdf]
Preview
PDF
Creative Commons Attribution.

5MB

Official URL: https://doi.org/10.3390/cancers12082282




Abstract

The complexity of hepatocellular carcinoma (HCC) challenges the identification of disease-relevant signals. C3G, a guanine nucleotide exchange factor for Rap and other Ras proteins, plays a dual role in cancer acting as either a tumor suppressor or promoter depending on tumor type and stage. The potential relevance of C3G upregulation in HCC patients suggested by database analysis remains unknown. We have explored C3G function in HCC and the underlying mechanisms using public patient data and in vitro and in vivo human and mouse HCC models. We found that C3G is highly expressed in progenitor cells and neonatal hepatocytes, whilst being down-regulated in adult hepatocytes and re-expressed in human HCC patients, mouse HCC models and HCC cell lines. Moreover, high C3G mRNA levels correlate with tumor progression and a lower patient survival rate. C3G expression appears to be tightly modulated within the HCC program, influencing distinct cell biological properties. Hence, high C3G expression levels are necessary for cell tumorigenic properties, as illustrated by reduced colony formation in anchorage-dependent and -independent growth assays induced by permanent C3G silencing using shRNAs. Additionally, we demonstrate that C3G down-regulation interferes with primary HCC tumor formation in xenograft assays, increasing apoptosis and decreasing proliferation. In vitro assays also revealed that C3G down-regulation enhances the pro-migratory, invasive and metastatic properties of HCC cells through an epithelial-mesenchymal switch that favors the acquisition of a more mesenchymal phenotype. Consistently, a low C3G expression in HCC cells correlates with lung metastasis formation in mice. However, the subsequent restoration of C3G levels is associated with metastatic growth. Mechanistically, C3G down-regulation severely impairs HGF/MET signaling activation in HCC cells. Collectively, our results indicate that C3G is a key player in HCC. C3G promotes tumor growth and progression, and the modulation of its levels is essential to ensure distinct biological features of HCC cells throughout the oncogenic program. Furthermore, C3G requirement for HGF/MET signaling full activation provides mechanistic data on how it works, pointing out the relevance of assessing whether high C3G levels could identify HCC responders to MET inhibitors.


Item Type:Article
Uncontrolled Keywords:C3G; hepatocarcinoma; cancer; MET; cell signaling
Subjects:Medical sciences > Medicine > Gastroenterology and Hepatology
Medical sciences > Medicine > Oncology
Medical sciences > Pharmacy > Molecular biology
ID Code:67532
Deposited On:27 Aug 2021 08:54
Last Modified:06 Sep 2021 09:17

Origin of downloads

Repository Staff Only: item control page